CD19 and acute lymphoblastic leukemia: Moreover, CD19/CD123 dual-target CAR-T cells and tri-specific CD19xCD20xCD22 CAR-T cells from Legend Biotech are also presented promising preclinical data for patients with B-ALL who relapsed from prior CAR-T cell therapies [22, 23].